Redeye updates its estimates and valuation following Lifco releasing its Q4 2024 report. Q4 figures beat our sales estimates, while margins roughly matched our projections. We judge Lifco’s performance despite economic uncertainty reinforces its best-in-class status. Still, the share’s current valuation leaves little margin for error, and we expect some multiple contraction to counteract earnings-growth-driven share price appreciation over time.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/